Supplementary Tables
Supplementary Table 1. The primer sequences for qRT-PCR

| Gene name |  | Sequence ( $5^{\prime}-3{ }^{\prime}$ ) |
| :---: | :---: | :---: |
|  | Forward | CTTCCACCAGCGGAACTACC |
| FOSB | Reverse | ACTGATCTGTCTCCGTCTCCT |
|  | Forward | GGACGGACCAAGCAGAGTTT |
| FSD2 | Reverse | GGACGGACCAAGCAGAGTTT |
|  | Forward | AGGGGTTCCTGGTCATACAC |
| LCP1 | Reverse | TCCATTGCCATCAGTATCAACT |
|  | Forward | GGACTGTCCTTTCGTGGCTC |
| HMGCS 1 | Reverse | GGCATGGTGAAAGAGCTGTG |
|  | Forward | TGCACCATGGGAAGAAAGAAGA |
| PLA2G4C | Reverse | TACGTGACGGCATCCAACAG |
|  | Forward | AGCTCTGTGTGAAGGTGCAG |
| CXCL8 | Reverse | TCTCAGCCCTCTTCAAAAACTTC |
|  | Forward | GTTCCGAGGTTGGAACACCT |
| MSMO1 | Reverse | TCTCTGGCTTATCCTGAACGG |
|  | Forward | GCTGTTCCCTGCGAAAGGTAT |
| IDI1 | Reverse | TGTTGCTTGTCGAGGTGGTT |
|  | Forward | TGGCATGCATGTAGCAGTGA |
| CLK4 | Reverse | GCATCTGGACACATCGGAAGA |
|  | Forward | TCTGGGCAGCAGGTTTACAA |
| BIRC3 | Reverse | CCCGAGATTAGACTAAGTCCCTT |
|  | Forward | TGCAGGAGGGTTCAAATCCG |
| N4BP3 | Reverse | AGGCAGCTGCTTCATGGTG |
|  | Forward | AGGTGGGTGAGGAAATCCAGA |
| AGR2 | Reverse | TCATCAAGGGTTTGTTGCTTGT |
|  | Forward | GGAACCTGAGGAGAGAGTGTTC |
| DDIT3 | Reverse | CTGCCATCTCTGCAGTTGGA |
|  | Forward | ACCCTTACAGGTAAGAATGGATCG |
| CPEB2 | Reverse | ACCTCGTCTTCGCCCATAAC |
|  | Forward | GAGAGAACATTGAGGCCCCC |
| MYBPH | Reverse | TTGCAGGTTGACCGTCTCTC |
|  | Forward | GTGTGGATAGAGCACGGCTG |
| CHRND | Reverse | CTGCCAGTCGAAGGGGAAAT |
|  | Forward | CAATGGAAACCCCCTCACGA |
| ZFHX2 | Reverse | GTGACAGCCAGTACCACCTC |
|  | Forward | CCTGATCTCTCCAAGTCCGC |
| PRR15 | Reverse | CAGCGGCCTGCTCGG |
|  | Forward | ATCGTGTGCACCTTCACCTA |
| KCNK3 | Reverse | GTGCCCGTAGCCGATG |
|  | Forward | CCATGGGACATCCCAGGTTTT |
| EPN3 | Reverse | TTCCTGAGGGGATCGGAGAC |


| CCR7 | Forward | GTCATGGACCTGGGTATGC |
| :---: | :---: | :---: |
|  | Reverse | TCCACTGTGGTGTTGTCTCC |
|  | Forward | CCGGCCGGGCTCTCAT |
| SLC1A7 | Reverse | TCCGGACATCAAGCTGGAGA |
|  | Forward | GCAGAGCGGCCAGCAA |
| LSP1 | Reverse | GCTTCAGGCTGAGGAGCATC |
|  | Forward | TGCAACACCCCTACAAGTGC |
| ADAMTSL2 | Reverse | GTTGGGCTGTTGTCCGTGG |
|  | Forward | ACGGACATGCAAGGTGTAGG |
| ALPK2 | Reverse | TTCTTTTCGCCTGGGGTCTC |
|  | Forward | AGAGATTGAGACTGCGTGGC |
| EIF2AK3 | Reverse | AGAGATTGAGACTGCGTGGC |
|  | Forward | ACTCCTGCGACCAGGTACT |
| PER1 | Reverse | GCCATGGGGAGAACAGAACA |
|  | Forward | GCTCCGAGGAACTTTCTCCC |
| KLF6 | Reverse | GCTCCGAGGAACTTTCTCCC |
|  | Forward | AGCCATGATCAGGCATTGGT |
| GBE1 | Reverse | GTAGCGAAGAAGGTCGTCGT |
|  | Forward | GTTTCCGTCGCCCTGATGTA |
| ADM | Reverse | GCATCCGGACTGCTGTCTT |
|  | Forward | GTACGAGTCGGCCAAGTTGA |
| GADD45B | Reverse | GTGTGAGGGTTCGTGACCA |
|  | Forward | GGGACTTGCTTCCAAAGGAAAA |
| HERPUD1 | Reverse | CCTTGGCGTTGATTTCTGGC |
|  | Forward | CAGCCAGGTCGGCAGTATAG |
| JUN | Reverse | GGACTCTGCCACTTGTCTCC |
|  | Forward | AGGCCCCGCCTCTAGTTC |
| ACSS2 | Reverse | AGGCCCCGCCTCTAGTTC |
|  | Forward | TCGCCCTGGAGTAATTTCGG |
| NOG | Reverse | CTGGGTGTTCGATGAGGTCC |
|  | Forward | CATCAACGAGCCTACGGCA |
| HSPA5 | Reverse | TCCATGACACGCTGGTCAAA |
|  | Forward | CTCCTCCTCGAAAGATGGCT |
| HDAC9 | Reverse | TTCCACATGAGGTCAGGCTGT |
|  | Forward | CTTGTCTCTGCAGACCGCT |
| NR1D1 | Reverse | CTTGTCTCTGCAGACCGCT |
|  | Forward | CAGGATGAAATTTGGCATGGGG |
| BBC3 | Reverse | CAGGATGAAATTTGGCATGGGG |
|  | Forward | GCGCACTAGAACGAGCAAG |
| TRAF6 | Reverse | GCGCACTAGAACGAGCAAG |
|  | Forward | ACTGCAACATCCAGATGGCA |
| IPMK | Reverse | ACTGCAACATCCAGATGGCA |
|  | Forward | AGAAAACCGTGGATGGAATTAGAA |
| CHMP2B | Reverse | AGAAAACCGTGGATGGAATTAGAA |


|  | Forward | GGTCAGTCCCGGGGATTTGT |
| :---: | :--- | :--- |
| KLF4 | Reverse | CAGTGGTAAGGTTTCTCACCTGTGT |
|  | Forward | ACATCAGCCAGAACAAGCGA |
| HSPA1A | Reverse | ACATCAGCCAGAACAAGCGA |
|  | Forward | CTAAAGGCCAGAAAGGTGCG |
| PPP1R15A | Reverse | ACGAAGGGACAGAGGAGGAA |
|  | Forward | CTGGGGAGAGCTGCCTAATG |
| PIM1 | Reverse | GCTCCCCTTTCCGTGATGAA |
| $\beta$-actin | Forward | GTCATTCCAAATATGAGATGCGT |
|  | Reverse | GCATTACATAATTTACACGAAAGCA |

## Supplementary Figures and figure legends:



Supplementary Figure 1. (a-c) The inhibition of the first 5 effective drug in all three osteosarcoma cell lines. (d) CCK-8 assay was used to detect the proliferation of osteoblast cell hFOB 1.19 after treatment with the IC30 and IC50 of ebastine.


Supplementary Figure 2. (a) Colony formation assays in osteosarcoma cells after treatment with the IC30 and IC50 of ebastine (magnification, $\times 40$ ). (b) Transwell assays in osteosarcoam cells after treatment with the IC30 and IC50 of ebastine (magnification, $\times 200$ ). (c-e) A wound-healing assay was used to determine cell migration after treatment with the IC30 and IC50 of ebastine (magnification, $\times 200$ ). Data are shown as the means $\pm$ SD from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05 ;{ }^{* *} P<0.01 ;{ }^{* * *}$ $P<0.001$.
a

b

c


Supplementary Figure 3. (a) Flow cytometry of cell cycle distribution in each phase after treatment with the IC30 and IC50 of ebastine after 48 h . (b) Flow cytometry of cell apoptosis distribution after treatment with the IC30 and IC50 of ebastine for 48 h . (c) Protein levels of cell cycle- and apoptosis-related proteins after treatment with ebastine for 48 h , assayed by Western blot. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05$; ** $P<0.01$.


Supplementary Figure 4. (a-b) Growth curve drawn by measuring the weight of mice on the indicated days in subcutaneous tumors and lung metastasis model. (c) HE staining of lung samples obtained from nude mice after injection with MNNG cells. (d) Diagram showing lung weight after treatment with ebastine. (e) HE staining of the heart, liver, spleen, lung, and kidney organs in ebastine-treated MNNG mice and control mice. Data are shown as the means $\pm \mathrm{SD}$ from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05$.


Supplementary Figure 5. (a) LC3 puncta were analyzed using the mRFP-GFP-LC3 construct after treatment with ebastine for 48 h . (b) Flow cytometry was used to analyze changes in apoptosis after treatment with ebastine for 48 h with or without 3-MA. Data are shown as the means $\pm \mathrm{SD}$ from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05 ; * * P<0.01$.


Supplementary Figure 6. (a) Protein levels of LC3B, ATG16 and ATG7 after treatment with the IC30 and IC50 of ebastine for 48 h , assayed by Western blot. (b) Autophagy-related proteins were analyzed by Western blot after treatment with ebastine for 48 h with or without 3-MA. Data are shown as the means $\pm$ SD from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} \mathrm{P}<0.05 ; * * \mathrm{P}<0.01$; *** $\mathrm{P}<0.001$.


Supplementary Figure 7. (a) A volcano plot analysis revealed 519 up-regulated and 460 downregulated genes. (b) The mRNA expression levels of 15 up-regulated and 11 down-regulated genes in osteosarcoma cells. (c) Heatmap displaying the mRNA expression levels of 15 up-regulated and 11 down-regulated genes in osteosarcoma cells. (d) Western blot showing the protein expression of p-MEK1 and LC3B after treatment with ebastine. (e) LC3 puncta were analyzed by the mRFP-GFP-LC3 construct after treatment with ebastine for 48 h with or without dorsomorphin. Data are shown as the means $\pm$ SD from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05 ;{ }^{* *} P<0.01 ;{ }^{* * *} P<0.001$.


Supplementary Figure 8. (a) Flow cytometry was used to analyze changes in apoptosis after treatment with ebastine for 48 h with or without dorsomorphin. (b) The relative protein levels of p -AMPK, ULK1, Beclin1, LC3B and Casp9 after treatment with ebastine for 48 h with or without dorsomophin. Data are shown as the means $\pm \mathrm{SD}$ from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05$; ${ }^{* *} P<0.01$.


Supplementary Figure 9. (a-c) The mRNA expression of 21 genes after treatment with ebastine in three osteosarcoma cell lines. (d) The relative mRNA expression of the 10 genes was determined by qRT-PCR after transfection with independent siRNAs in MNNG cells. (e) LC3 puncta were analyzed by the mRFP-GFP-LC3 construct after treatment with ebastine for 48 h with or without knockdown of IPMK. Data are shown as the means $\pm$ SD from at least three independent experiments. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05 ;{ }^{* *} P<0.01$; ${ }^{* * *}$ $P<0.001$.


Supplementary Figure 10. (a) Protein levels of apoptosis, autophagy, IPMK, and p-AMPKK in osteosarcoma cells treated with ebastine for 48 h with or without knockdown of IPMK. (b) Protein expression of IPMK, p-AMPK, ULK1, LC3B, and CDK2 and cleavage of caspase-9 were analyzed by western blot in tumor tissues. Statistical analysis was performed using Student's t-test. Error bars represent the SEM. ${ }^{*} P<0.05$.


Supplementary Figure 11. (a-c) IHC analysis of the related proteins ULK1, CDK2, and caspase-9.

